microRNA在肝癌诊断、治疗和预后中的作用研究进展

doi:10.3969/j.issn.1004-616x.2015.04.016

癌变·畸变·突变 ›› 2015, Vol. 27 ›› Issue (4): 325-328.doi: 10.3969/j.issn.1004-616x.2015.04.016

• 综述 • 上一篇

microRNA在肝癌诊断、治疗和预后中的作用研究进展

宋蕾¹, 王昭², 张焕铃¹

1. 河北医科大学实验动物学部, 河北省实验动物重点实验室, 河北石家庄 050017;
2. 河北医科大学基础医学院, 河北石家庄 050017

收稿日期:2015-01-06 修回日期:2015-06-10 出版日期:2015-07-30 发布日期:2015-07-30
作者简介:宋蕾,E-mail:songlei007123@163.com。
基金资助:
河北省自然科学基金(C2012206096);河北省科技条件建设课题(12966121D);河北省卫生厅医学科学研究重点课题计划(20100039)

Received:2015-01-06 Revised:2015-06-10 Online:2015-07-30 Published:2015-07-30
Contact: 张焕铃,E-mail:lha78@163.com E-mail:lha78@163.com

摘要/Abstract

摘要： 肝癌是人类常见的恶性肿瘤之一,目前缺乏有效的诊断和治疗技术,死亡率居高不下。microRNA(miRNA)是一类内源性非编码的小RNA,研究显示,多种miRNA在正常组织和肝癌组织间存在表达差异,与肿瘤的发生发展密切相关。miR-21、miR-106a、miR-34等与肝癌的发生有关;miR-92、miR-20等与肝癌的分化有关;而miR-30d、miR-21与肝癌的增生、迁移和侵袭有关。肝癌进程中关键的miRNA及其作用靶点是近年来的研究热点,有望为肝癌诊断、治疗和预后提供新的途径。研究发现miR-375、miR-199a、miR-122等可作为潜在的肝癌诊断标志物应用于肝癌诊断;miR-195、miR-26a、miR-127等可应用于肝癌治疗;miR-221、miR-99b、miR-let-7g等被认为与肝癌术后的预后有关,还有一些其他分子可作为肝癌细胞侵袭、转移的调节分子并用于判断预后。本文就miRNA在肝癌的诊断、治疗、预后方面的研究作一综述。

关键词: 肝癌, microRNA, 基因, 蛋白, 表达水平

中图分类号:

R730.2

宋蕾, 王昭, 张焕铃. microRNA在肝癌诊断、治疗和预后中的作用研究进展[J]. 癌变·畸变·突变, 2015, 27(4): 325-328.

参考文献

[1] 陈彪. miRNA在原发性肝癌中的研究进展[J]. 临床肿瘤学杂志,2012,17(10):946-950.
[2] Pineau P,Volinia S,McJunkin K,et al. MiR-221 overexpression contributes to liver tumorigebesis[J]. Proc Natl Acad Sci USA,2010, 107(1):264-269.
[3] Meng F,Henson R,Wehbe-Janek H,et al. MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer[J]. Gastroenterology,2007,133(2):647-658.
[4] Pogribny IP,Tryndyak VP,Boyko A,et al. Induction of microRNA omederegulation in rat liver by long-term tamoxifen exposure[J]. Mutat Res,2007,619(1/2):30-37.
[5] Murakami Y,Yasuda T,Saigo K,et al. Comprehensive analysis of microRNA expression patterns in hepatocelular carcinoma and nontumorous tissues[J]. Oncogene,2006,25(17):2537-2545.
[6] Yao J,Liang L,Huang S,et al. MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in Hepatocellular carcinoma[J]. Hepatology,2010,51(3):846-856.
[7] Garcon M,Di leva C,Romano,et al. miRNA-221 and miRNA-222 regulate TRALI,resistance and enhance tumorigenicity through PTEN and TIMP3 nonregulated[J]. Cancer Cell,2009,16(6):498-509.
[8] Mi-Kyung Song,Yong-Keun Park,Jae-Chun Ryu,et al. Polycyclic aromatic hydrocarbon (PAH)-mediated upregulation of hepatic microRNA-181 family promotes cancer cell migration by targeting MAPK phosphatase-5,regulating the activation of p38 MAPK[J]. Toxicol Appl Pharmacol,2013,273(1):130–139.
[9] Su H,Yang JR,Xu T,Huang J,et al. MicroRNA-101, downregulated in hepatocellular carcinoma,promotes apoptosis and suppresses tumorigenicity[J]. Cancer Res,2009,69(3):1135-1142.
[10] Xiong Y,Fang JH,Yun JP,et al. Effects of microRNA-29 on apoptosis,tumori-genicity,and prognosis of hepatocellular carcinoma [J]. Hepatology,2010,51:836-845.
[11] Zheng Y,Yin L,Chen H,et al. MiR-376a suppresses profilerationg and induces apoptosis in hepatocellular carcinoma[J]. FEBS Lett, 2012,586(16):2396-2403.
[12] Li LM,Hu ZB,Zhou ZX,et al. Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma[J]. Cancer Res,2010,70(23):9798-9807.
[13] Qu KZ,Zhang K,Li H,et al. Cobalt and Inorganic Cobalt Compounds [J]. J Clin Gastroenterol,2011,45(4): 355-360.
[14] Florie B,Pavlina K,Peter LM,et al. Diagnostic and therapeutic potential of miRNA signatures in patients with hepatocellular carcinoma[J]. J Hepatol,2012,56(6):1371-1383.
[15] Sukata T,Sumida K,Kushida M,et al. Circulating microRNAs, possible indicators of progress of rat hepatocarcinogenesis from early stages[J]. Toxicol Lett,2011,200(1/2):46-52.
[16] 刘建华,程涛,王洪敏,等. 血清miRNA表达水平检测与原发性肝癌早期诊断的研究[J]. 热带医学杂志,2010,10(6):666-668.
[17] Yamamoto Y,Kosaka N,Tanaka M,et al. MicroRNA-500 as a potential diagnostic marker for hepatocelluar carcinoma[J]. Biomarkers, 2009,14(7):529-538.
[18] Kota J,Chivukula RR,ODonnell KA,et al. Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model[J]. Cell,2009,137(6):1005-1017.
[19] 漆仲春,李华,李东,等. MicroRNA在原发性肝癌中的研究进展[J]. 肿瘤预防与治疗,2012,25(6):389-393.
[20] Gramantieri L,Ferracin M,Fornari F,et al. Cyclin G1 is a target of miR-122a,a microRNA frequently domn-regulated in human hepatocellular carcinoma[J]. Cancer Res,2007,67(13):6092-6099.
[21] Lin CJ,Gong HY,Tseng HC,et al. miR-122 targets an anti-apoptotic gene,Bcl-w,in human hepatocellular carcinoma cell lines[J]. Biochem Res Commun,2008,375(3):315-320.
[22] Lamba V,Ghodke Y,Guan W,et al. microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450[J]. Biochem Biophys Res Commun,2014,445(2):404-411.
[23] Fornari F,Gramantieri L,Milazzo M,et al. microRNA-519d is up-regulated in hepatocellular carcinoma and sensitizes HCC cells to doxorubicin treatment by targeting CDKN1A/P21[J]. J Hepatol,2011, 54(Sup 1):88.
[24] 张勇,李德春,郭子健,等. Stat3 mRNA 靶向MicroRNA 重组质粒的构建及其在HepG2 肝癌细胞系中的表达[J]. 苏州大学学报:医学版,2011,31(4):543-548.
[25] Ma L,Liu J,Shen J,et al. Expression of rniRNA-122 mediated by adenoviral vector induces apoptosis and cell cycle arrest of cacer cells[J]. Cancer Bio Ther,2010,9(7):554-561.
[26] Saito Y,Liang G,Egger G,et al. Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells[J]. Cancer Cell,2006, 9(6):435-443.
[27] Sato F,Hatano E,Kitamura K,et al. MicroRNA profile predicts recurrence after resection in patients with hepatocellular carcinoma within the Milan Criteria[J]. PLoS ONE,2011,6(1):el6435.
[28] Jiang J,Gusev Y,Aderca I,et al. Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis,and patient survival[J]. Clin Cancer Res,2008, 14(2): 419-427.
[29] Budhu A,Jia HL,Forgues M,et al. Identification of metastasis-related microRNAs in hepatocellulae caicinoma[J]. Hepatology,2008, 47(3):897-907.
[30] Huang YH,Lin KH,Chen HC,et al. Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma[J]. PLoS ONE,2012,7(5):e37188.
[31] Ji J,Yu L,Yu Z,et al. Development of a miR-26 Companion diagnostic test for adjuvant interferon-alpha therapy in hepatocellular Carcinoma[J]. Int J Biol Sci,2013,9(3):303-312.
[32] 张志成. miRNA在肝细胞癌中的研究进展[J]. 中国误诊学杂志,2011,11(32):7839-7840.

microRNA在肝癌诊断、治疗和预后中的作用研究进展

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	郭玉凤, 孔晓娜, 张婷, 张超, 薛振伟, 李建军, 张晶, 周小林. 2015—2019年某焦化厂下风向居民血清免疫球蛋白分析[J]. 癌变·畸变·突变, 2022, 34(1): 14-19.
[2]	国瑞贤, 谢广云, 韩莹. 基于转录组测序方法研究加替沙星对小鼠的肝损伤作用[J]. 癌变·畸变·突变, 2022, 34(1): 20-24.
[3]	彭友彬, 林浩, 黎明, 黄海花. TPX2在非肌层浸润性膀胱癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2022, 34(1): 30-34.
[4]	祝欣萍, 贾迪, 林少辉, 刘晨, 李婧铱, 赵炜明. 新型多金属氧酸盐药物{BiW₈O₃₀}对肝癌SK-HEP-1细胞的抑制作用[J]. 癌变·畸变·突变, 2022, 34(1): 47-52,66.
[5]	陈敏娜, 李春兰, 刘静. 转录因子STAT5A启动子荧光素酶报告基因质粒的构建及鉴定[J]. 癌变·畸变·突变, 2022, 34(1): 53-56,71.
[6]	王苗, 王全凯, 李昕苇, 马顺鹏, 乌瀚宝栎尔, 许建宁. 甲基丙烯酸环氧丙酯诱导16HBE细胞恶性转化相关m⁶A修饰异常mRNA的分析[J]. 癌变·畸变·突变, 2021, 33(6): 405-409.
[7]	杨婵君, 陈雯恬, 刘静. 胶原蛋白作为胃癌潜在生物标志物的生物信息学分析[J]. 癌变·畸变·突变, 2021, 33(6): 410-419.
[8]	焦文鹏, 侯琳, 崔妹娟, 焦文静, 马鸣, 张金艳. miR-93-5p和miR-106b-5p在酒精相关性肝癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(6): 430-434.
[9]	方煜彤, 张群琛, 洪超群, 陈春发, 陈炯玉, 张任栋, 吴俊东. 乳腺癌中miR-221、miR-222表达水平对GATA3和FOXA1蛋白的影响及其作用机制[J]. 癌变·畸变·突变, 2021, 33(6): 435-441,460.
[10]	高晓斌, 武雪亮, 王胜杰, 孙光源, 王文静, 梁峰, 赵轶峰, 刘振显, 张迎春. TRIM59在结直肠癌中的表达及其与临床病理指标的关系[J]. 癌变·畸变·突变, 2021, 33(6): 446-450.
[11]	兰尤, 陈圆圆, 林忠宁, 林育纯. 病毒致癌过程中的线粒体糖酵解代谢重编程机制研究进展[J]. 癌变·畸变·突变, 2021, 33(6): 470-474.
[12]	杨兴肖, 张雪原, 邹乃祎, 单保恩, 马鸣, 祝淑钗. 干扰HMGB1基因表达对食管鳞癌细胞侵袭迁移及放射敏感性的影响[J]. 癌变·畸变·突变, 2021, 33(5): 327-333.
[13]	陆雪梅, 许铭炎, 刘庭英, 张秋芳, 邓小玲. 潮汕地区汉族人群MTHFR基因rs1801131多态性与非综合征型唇腭裂的相关性研究[J]. 癌变·畸变·突变, 2021, 33(5): 334-337,344.
[14]	杨荔艳, 刘奏, 郝佳洁, 张钰, 王明荣. p62蛋白在食管鳞癌细胞中核浆易位的机制研究[J]. 癌变·畸变·突变, 2021, 33(5): 338-344.
[15]	焦文静, 张金艳, 马鸣, 郭秀娟, 冯军花, 邵俊国, 焦文鹏. 异黏蛋白与叉头框蛋白M1在肝细胞癌中的表达及其临床意义[J]. 癌变·畸变·突变, 2021, 33(5): 349-353,359.